Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Michael S. Brown Sells 1,535 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Free Report) Director Michael S. Brown sold 1,535 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $1,040.00, for a total value of $1,596,400.00. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,437,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Regeneron Pharmaceuticals Stock Down 0.6 %

Shares of REGN opened at $1,039.11 on Thursday. The company has a market capitalization of $114.50 billion, a price-to-earnings ratio of 30.70, a PEG ratio of 2.15 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a 52 week low of $684.80 and a 52 week high of $1,052.34. The stock’s 50-day moving average price is $962.39 and its 200-day moving average price is $940.36. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). The company had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current year.

Analysts Set New Price Targets

REGN has been the topic of a number of analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research report on Monday. Truist Financial reaffirmed a “buy” rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. Morgan Stanley raised their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price on the stock. Finally, Royal Bank of Canada raised their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,229.00 and gave the stock an “outperform” rating in a report on Wednesday, June 12th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $998.09.

Read Our Latest Stock Analysis on REGN

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in REGN. West Paces Advisors Inc. raised its position in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares during the period. Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $28,000. Fortitude Family Office LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $31,000. MCF Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 12 shares in the last quarter. Finally, BOK Financial Private Wealth Inc. acquired a new position in Regeneron Pharmaceuticals in the 1st quarter worth about $37,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

(Get Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

See Also

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.